Carboplatin-Tranet Dosage/Direction for Use

This medicine will be administered by infusion (drip) into a vein over 15-60 minutes.
Dose: The correct dose of carboplatin and how often it must be given should be determined.
The dose will depend on the medical condition, size and how well the kidneys are working. Patients should be informed how well their kidneys are working using blood or urine samples. Regular blood tests should be performed after the dose of carboplatin. Patients may also have checks for nerve damage and hearing loss.
There is likely to be about 4 weeks between each dose of carboplatin.
Instructions for use - Cytotoxic: Carboplatin should be used by the intravenous route only. The recommended dosage of carboplatin in previously untreated adult patients with normal kidney function, i.e. creatinine clearance >60 ml/min, is 400 mg/m² as a single short-term IV dose administered by a 15- to 60-minute infusion. Alternatively, the Calvert formula shown in the following table may be used to determine dosage: See table.

Click on icon to see table/diagram/image

Therapy should not be repeated until four weeks after the previous carboplatin course and/or until the neutrophil count is at least 2,000 cells/mm³ and the platelet count is at least 100,000 cells/mm³.
Reduction of the initial dosage by 20-25% is recommended for those patients who present with risk factors such as prior myelosuppressive treatment and low performance status (ECOG-Zubrod 2-4 or Karnofsky below 80).
Determination of the haematological nadir by weekly blood counts during the initial courses of treatment with Carboplatin Infusion is recommended for future dosage adjustment.
Impaired renal function: In patients with impaired renal function, dosage of carboplatin should be reduced (refer to Calvert formula) and haematological nadirs and renal function monitored.
Patients with creatinine clearance values of less than 60 ml/min are at greater risk to develop myelosuppression. The frequency of severe leukopenia, neutropenia, or thrombocytopenia has been maintained at about 25% with the following dosage recommendations: Combination Therapy: The optimal use of Carboplatin Infusion in combination with other myelosuppressive agents requires dosage adjustments according to the regimen and schedule to be adopted.
Paediatric patients: The safety and efficacy of carboplatin in children has not yet been established. No data are available. As no sufficient experience of carboplatin use in children is available, no specific dosage recommendations can be given.
Elderly: In the case of patients aged over 65, the carboplatin dosage needs to be adjusted to their general state of health during the first and subsequent courses of treatment.
Dilution and Reconstitution: The product must be diluted prior to infusion, with 5% glucose solution or 0.9% sodium chloride solution, to concentrates as low as 0.5 mg/ml.
Discontinuation of Carboplatin Infusion: Patients should be advised if they have any further questions on the use of this product.